Nuwellis Introduces New 24-Hour Aquadex™ Circuit to Support Hospital-Based Outpatient and Short-Term Fluid Management

Rhea-AI Summary

Nuwellis (NASDAQ:NUWE) announced the upcoming launch of a new 24-hour circuit for Aquadex therapy in the United States this fall. This addition complements their existing 72-hour circuit option, enabling hospitals to better match supply with care settings while maintaining consistent therapy delivery.

The new circuit is specifically designed for single-day outpatient sessions, supporting hospitals in building outpatient Aquadex programs that deliver scheduled fluid removal treatment without requiring hospital admission. The innovation aims to streamline clinic operations, enhance scheduling efficiency, and increase treatment capacity while providing patients with convenient same-day visits.

Positive

• Introduction of new 24-hour circuit expands product portfolio
• Enables hospitals to scale outpatient treatment capacity
• Supports more efficient clinic operations and scheduling
• Potential to increase adoption of Aquadex therapy in ambulatory settings

Negative

• Implementation may require additional staff training and resources
• Success depends on hospital adoption and program implementation

Insights

Medical Technology Analyst

Nuwellis expands Aquadex product line with 24-hour circuit targeting outpatient fluid management, potentially increasing market reach.

Nuwellis's introduction of a 24-hour Aquadex circuit represents a strategic expansion of their fluid management technology into the growing hospital-based outpatient market. The new circuit complements their existing 72-hour option and is specifically designed to align with single-day outpatient workflows.

This product line extension addresses several operational challenges hospitals face. By matching supply duration to care setting, hospitals can potentially optimize inventory management and reduce waste while maintaining consistent therapy experiences across settings. The single-day circuit particularly supports the growing trend of shifting appropriate fluid management cases from inpatient to outpatient settings, which typically carry lower reimbursement hurdles and better margins for providers.

From a market perspective, this move suggests Nuwellis recognizes the healthcare system's continued shift toward outpatient care where clinically appropriate. By providing both 24-hour and 72-hour options, the company creates flexibility for hospitals implementing fluid management programs across different settings, potentially expanding their addressable market.

The announcement also indicates Nuwellis is providing implementation resources beyond just the device, including guidance on patient identification, implementation workflows, and staff education. This comprehensive approach suggests they're focused on driving adoption by reducing barriers to implementation rather than simply selling equipment.

MINNEAPOLIS, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc., a fluid management company, announced plans to introduce a new 24-hour circuit for Aquadex therapy in the United States this fall. The new circuit is designed for single-day outpatient sessions and complements the company’s existing 72-hour option that is commonly used for multi-day therapy or inpatient care. Together, these options help hospitals match supply to setting while maintaining a consistent therapy experience.

Hospitals are building outpatient Aquadex programs to deliver predictable, scheduled care for patients who need fluid removal without a hospital admission. The 24-hour circuit supports that model by aligning with single-visit workflows, easing scheduling, and program planning. For patients, the goal is a straightforward same-day visit. For providers and administrators, the aim is a reliable pathway to run more efficient clinics and scale capacity.

“Hospital-based outpatient Aquadex therapy is growing as a reliable option for patients who need fluid removal without a hospital admission. The 24-hour circuit supports that model with a straightforward single-visit pathway,” said John Erb, Chairman of the Board and Chief Executive Officer of Nuwellis. “This addition is about meeting sites where they are, helping teams expand access to Aquadex therapy in a clinic setting and supporting consistent, high-quality care across both outpatient and inpatient programs.”

Nuwellis provides program resources for hospital-based outpatient sites, including patient identification, implementation guidance, and staff education to help teams add or expand Aquadex therapy in ambulatory settings.

For more information, visit www.nuwellis.com.

About Nuwellis Nuwellis, Inc. (Nasdaq: NUWE) is a medical device company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on commercializing the Aquadex SmartFlow^® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, with a wholly owned subsidiary in Ireland. For more information visit www.nuwellis.com or visit us on LinkedIn or X, formerly known as Twitter.

About the Aquadex SmartFlow^® System The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.

Forward-Looking Statements Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2025 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether due to new information, future events or otherwise.

For further information, please contact:

Investor Relations:
Jenene Thomas
JTC Investor Relations
NUWE@jtc.com

Media Contact:
Leah McMullen
Director of Communications
Leah.mcmullen@nuwellis.com

FAQ

What is the new Aquadex circuit announced by Nuwellis (NUWE)?

Nuwellis announced a new 24-hour circuit for Aquadex therapy, designed specifically for single-day outpatient fluid management sessions, complementing their existing 72-hour circuit option.

When will Nuwellis (NUWE) launch the new 24-hour Aquadex circuit?

Nuwellis plans to introduce the new 24-hour Aquadex circuit in the United States in fall 2025.

What are the benefits of Nuwellis (NUWE) new 24-hour Aquadex circuit?

The new circuit enables single-day outpatient treatments, streamlines clinic operations, improves scheduling efficiency, and helps hospitals scale their treatment capacity without requiring hospital admissions.

How does Nuwellis (NUWE) support hospitals implementing the Aquadex therapy?

Nuwellis provides comprehensive program resources including patient identification, implementation guidance, and staff education to help hospitals add or expand Aquadex therapy in ambulatory settings.

What is the difference between Nuwellis (NUWE) 24-hour and 72-hour Aquadex circuits?

The 24-hour circuit is designed for single-day outpatient sessions, while the 72-hour circuit is used for multi-day therapy or inpatient care, allowing hospitals to match supply to different care settings.